A5033285318- Nausea and vomiting management
- Cancer Treatment and Pharmacology
- Anesthesia and Pain Management
- Neutropenia and Cancer Infections
- Breast Cancer Treatment Studies
- Erythropoietin and Anemia Treatment
- Pathogenesis and Treatment of Hiccups
- Frailty in Older Adults
- Iron Metabolism and Disorders
- Advances in Oncology and Radiotherapy
- Bone health and treatments
- Biosimilars and Bioanalytical Methods
- Colorectal Cancer Treatments and Studies
- Health Systems, Economic Evaluations, Quality of Life
- Cancer survivorship and care
- Advanced Breast Cancer Therapies
- Chemotherapy-related skin toxicity
- Blood disorders and treatments
- HER2/EGFR in Cancer Research
- Palliative Care and End-of-Life Issues
- Economic and Financial Impacts of Cancer
- Chemotherapy-induced organ toxicity mitigation
- Pharmacological Effects and Toxicity Studies
- Lung Cancer Treatments and Mutations
- Nutrition and Health in Aging
Clinique de Genolier
2016-2025
Breast Center
2015-2024
European CanCer Organisation
2019-2023
European School of Oncology
2000-2021
Hudson Institute
2018
John Wiley & Sons (United States)
2018
Ospedale A. Perrino
2018
Hospital Arnau de Vilanova
2018
Hospital Universitario Virgen del Rocío
2018
Lublin Oncology Center
2018
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years 5-year only ∼25% [2–4]. Some more recent series seem to indicate improvement in [5, 6].
Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic (MBC) [1.Cardoso F. Costa A. Norton L. ESO-ESMO 2nd International Consensus Guidelines for (ABC2). Simultaneous publication in.Breast. 2014; 23: 489-502Abstract Full Text PDF PubMed Scopus (252) Google Scholar]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of ∼3 years 5-year only ∼25% [2.Cardoso Spence D. Mertz S. et al.Global analysis...
PURPOSE: To appraise the performance of Comprehensive Geriatric Assessment (CGA) in elderly cancer patients (≥ 65 years) and to evaluate whether it could add further information with respect Eastern Cooperative Oncology Group status (PS). PATIENTS AND METHODS: We studied 363 (195 males, 168 females; median age, 72 solid (n = 271) or hematologic 92) tumors. In addition PS, their physical function was assessed by means activity daily living (ADL) instrumental activities (IADL) scales....
PURPOSE: To appraise the performance of Comprehensive Geriatric Assessment (CGA) in elderly cancer patients (≥ 65 years) and to evaluate whether it could add further information with respect Eastern Cooperative Oncology Group status (PS). PATIENTS AND METHODS: We studied 363 (195 males, 168 females; median age, 72 solid (n = 271) or hematologic 92) tumors. In addition PS, their physical function was assessed by means activity daily living (ADL) instrumental activities (IADL) scales....
PURPOSE: This phase III study compared docetaxel with mitomycin plus vinblastine (MV) in patients metastatic breast cancer (MBC) progressing despite previous anthracycline-containing chemotherapy. PATIENTS AND METHODS: Patients (n = 392) were randomized to receive either 100 mg/m 2 intravenously (IV) every 3 weeks 203) or 12 IV 6 189), for a maximum of 10 3-week cycles. RESULTS: In an intention-to-treat analysis, produced significantly higher response rates than MV overall (30.0% v 11.6%; P...
Advanced breast cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality life. Due continuous research, several advances have been made, particularly for the human epidermal growth factor receptor 2 (HER-2)-positive luminal-like subtypes. Notwithstanding these advances, median overall survival patients with ABC only 2–3 years, although range wide [1–5], may be longer treated in specialized institutions [6].
•The clinical course of advanced cancer for many patients with bone metastases can be transformed through optimum multidisciplinary management.•Bone-targeted agents significantly reduce skeletal morbidity in across tumour types and should part standard treatment.•Treatment-induced loss increases fracture risk may require use a bone-targeted agent addition to lifestyle modifications.•The bisphosphonate adjuvant therapies postmenopausal early breast reduces recurrence improves survival.